Ulrike Gnad-Vogt, MD

Interim Chief Development Officer

Ulrike Gnad-Vogt joined CureVac in 2011 as Head of Clinical Development and served as Chief Medical Officer from 2013-2019. During this time, she was responsible for clinical development and regulatory affairs in all therapeutic areas. Since 2019, she has served as Therapeutic Area Head of Oncology and led the biomarker/translational medicine department. Before joining CureVac, Ulrike held positions as Attending Oncologist at the National Center for Tumor Diseases in Heidelberg and Global Medical Leader at Merck KGaA, where she focused on early clinical development of cancer vaccines and immunocytokines. She has practiced clinical medicine for more than nine years across different University Hospitals with a focus on internal medicine, hematology and medical oncology. Ulrike holds an MD from University of Homburg/Saar and board certifications in internal medicine, hematology and medical oncology.

Back to Executive Board